Catalent CEO Alessandro Maselli speaks with John Carroll at Endpoints' JPM24 event (Brian Benton Photography)
February 9, 2024 11:29 AM ESTUpdated 01:40 PM
Manufacturing

Catal­ent, which is be­ing ac­quired by No­vo, re­ports 10% drop in sec­ond-quar­ter rev­enue

Anna Brown

News Reporter

Four days af­ter No­vo Hold­ings an­nounced plans to buy Catal­ent for $16.5 bil­lion, the CD­MO re­vealed its fi­nan­cial health in its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times